Canada will be short 82,000 doses in next shipment of Moderna COVID-19 vaccine - National Post | Canada News Media
Connect with us

Business

Canada will be short 82,000 doses in next shipment of Moderna COVID-19 vaccine – National Post

Published

 on


Maj.-Gen. Dany Fortin said Thursday Moderna assured the government Canada will receive the full two million doses it was promised by the end of March

Article content

Canada will receive 82,000 fewer doses of the Moderna COVID-19 vaccine in the next shipment, leaving the company to fill a 1.3-million dose shortfall in March in order to meet the federal government’s targets.

The reduction is the latest blow to the federal government’s vaccine deliveries which have also seen Pfizer significantly reducing the doses Canada has received in recent weeks.

Maj.-Gen. Dany Fortin, who is in charge of the federal vaccine rollout, said Thursday Moderna had assured the government Canada will receive the full two million doses it was promised by the end of March.

“We have no reason to doubt that. We’re in constant discussion with them,” he said at a press conference in French.

The next shipment of Moderna is expected to arrive in Canada the week of Feb. 22, and will include 168,000 doses, Fortin said. That’s down from the 250,000 the government had originally expected.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

Fortin said the government has been told to expect another two shipments to arrive in March, though he couldn’t specify exactly when they will arrive or the amount of vaccines that will be included in each shipment.

Moderna began regular delivery of its vaccine in December. Its last shipment at the beginning of the month was also about 20 per cent short of what the company had promised. By the end of February, Moderna will have delivered just short of 700,000 doses in just over two months.

Fortin also said the government still expects to receive the promised four million doses of the Pfizer BioNTech vaccine by the end of March. Pfizer was supposed to deliver 1.15 million doses of its vaccine over the past four weeks, but instead only received 339,000, according to the Canadian Press.

That rollout is set to accelerate in the coming weeks, with the government counting on approximately 403,000 doses arriving next week, 475,000 the last week of February and 444,000 in each week of the first two weeks of March.

Those numbers “reflect the recent label change authorization from Health Canada,” Fortin noted. Pfizer initially counted five vials per dose in its vaccine. After health care providers realized they could extract six doses, the company asked Health Canada to recognize that each vial contains six doses, which the regulator did Tuesday.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

The government has ordered 64 million of specialized low-dead space syringes that help extract more liquid from each dose of the vaccine.

Fortin said the government is in the process of distributing the syringes. “In some cases they will arrive in the coming couple of days. All provinces will have sufficient quantities for the next several weeks, and more are coming,” he said.

Dr. Howard Njoo, Canada’s deputy chief public health officer, added the government held English-language webinar training with 1,800 participants on techniques for vaccinators to use to extract the sixth dose, and will hold another in French, as well as additional educational support. “We’re supporting the provinces and territories,” he said.

To date, the government has distributed a total of 1.4 million doses of both vaccines, Fortin said.

Also on Thursday, the Manitoba government announced it had reached its own deal for two million doses of a Canada-made vaccine, contingent on that vaccine receiving regulatory approval from Health Canada. Providence Therapeutics’ mRNA vaccine began Phase 1 human trials late last month.

Dr. Howard Njoo, Canada’s Deputy Chief Public Health Officer. Photo by Sean Kilpatrick/The Canadian Press/File

When asked about Manitoba’s deal, Dr. Njoo was skeptical about the idea of provinces going on their own to strike vaccine agreements, noting Health Canada is the only regulator in the country that can approve vaccines.

“I’m not quite sure I understand in terms of how quite how individual jurisdictions may enter into any sort of agreement at this point with any sort of unapproved products,” he said in the press conference. “I think we need to wait for Health Canada to get a submission… and go through the very strict and regulatory process for approval.”

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

He added economies of scale apply to vaccine procurement, and that “it’s in some ways better for… the government of Canada as a bulk buyer on behalf of Canada and provinces and territories.”

Manitoba Premier Brian Pallister said in the press release announcing the Providence Therapeutics agreement that the province has been reliant on the federal government buying vaccines that are manufactured outside of Canada, which has resulted in Canadians being slower to receive vaccines than residents of many other countries.

Officials were asked about why Canada lags other countries, such as the U.K., at the press conference Thursday. In the U.K., nearly 20 per cent of the population has received at least one dose of the vaccine, in comparison to 1.7 per cent of Canadians, according to data compiled by Bloomberg.

“It’s always challenging to compare different countries, because every country has its own particular context. Geographical factors, the way the health care system is set up, and so forth,” Dr. Njoo said. He added that although the vaccine rollout may be going faster in the U.K., the country is “having a tough time with COVID-19 in general.”

“I think it’s not just vaccination itself that should be looked at,” Dr. Njoo said.

Comments

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Japan’s SoftBank returns to profit after gains at Vision Fund and other investments

Published

 on

 

TOKYO (AP) — Japanese technology group SoftBank swung back to profitability in the July-September quarter, boosted by positive results in its Vision Fund investments.

Tokyo-based SoftBank Group Corp. reported Tuesday a fiscal second quarter profit of nearly 1.18 trillion yen ($7.7 billion), compared with a 931 billion yen loss in the year-earlier period.

Quarterly sales edged up about 6% to nearly 1.77 trillion yen ($11.5 billion).

SoftBank credited income from royalties and licensing related to its holdings in Arm, a computer chip-designing company, whose business spans smartphones, data centers, networking equipment, automotive, consumer electronic devices, and AI applications.

The results were also helped by the absence of losses related to SoftBank’s investment in office-space sharing venture WeWork, which hit the previous fiscal year.

WeWork, which filed for Chapter 11 bankruptcy protection in 2023, emerged from Chapter 11 in June.

SoftBank has benefitted in recent months from rising share prices in some investment, such as U.S.-based e-commerce company Coupang, Chinese mobility provider DiDi Global and Bytedance, the Chinese developer of TikTok.

SoftBank’s financial results tend to swing wildly, partly because of its sprawling investment portfolio that includes search engine Yahoo, Chinese retailer Alibaba, and artificial intelligence company Nvidia.

SoftBank makes investments in a variety of companies that it groups together in a series of Vision Funds.

The company’s founder, Masayoshi Son, is a pioneer in technology investment in Japan. SoftBank Group does not give earnings forecasts.

___

Yuri Kageyama is on X:

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Trump campaign promises unlikely to harm entrepreneurship: Shopify CFO

Published

 on

 

Shopify Inc. executives brushed off concerns that incoming U.S. President Donald Trump will be a major detriment to many of the company’s merchants.

“There’s nothing in what we’ve heard from Trump, nor would there have been anything from (Democratic candidate) Kamala (Harris), which we think impacts the overall state of new business formation and entrepreneurship,” Shopify’s chief financial officer Jeff Hoffmeister told analysts on a call Tuesday.

“We still feel really good about all the merchants out there, all the entrepreneurs that want to start new businesses and that’s obviously not going to change with the administration.”

Hoffmeister’s comments come a week after Trump, a Republican businessman, trounced Harris in an election that will soon return him to the Oval Office.

On the campaign trail, he threatened to impose tariffs of 60 per cent on imports from China and roughly 10 per cent to 20 per cent on goods from all other countries.

If the president-elect makes good on the promise, many worry the cost of operating will soar for companies, including customers of Shopify, which sells e-commerce software to small businesses but also brands as big as Kylie Cosmetics and Victoria’s Secret.

These merchants may feel they have no choice but to pass on the increases to customers, perhaps sparking more inflation.

If Trump’s tariffs do come to fruition, Shopify’s president Harley Finkelstein pointed out China is “not a huge area” for Shopify.

However, “we can’t anticipate what every presidential administration is going to do,” he cautioned.

He likened the uncertainty facing the business community to the COVID-19 pandemic where Shopify had to help companies migrate online.

“Our job is no matter what comes the way of our merchants, we provide them with tools and service and support for them to navigate it really well,” he said.

Finkelstein was questioned about the forthcoming U.S. leadership change on a call meant to delve into Shopify’s latest earnings, which sent shares soaring 27 per cent to $158.63 shortly after Tuesday’s market open.

The Ottawa-based company, which keeps its books in U.S. dollars, reported US$828 million in net income for its third quarter, up from US$718 million in the same quarter last year, as its revenue rose 26 per cent.

Revenue for the period ended Sept. 30 totalled US$2.16 billion, up from US$1.71 billion a year earlier.

Subscription solutions revenue reached US$610 million, up from US$486 million in the same quarter last year.

Merchant solutions revenue amounted to US$1.55 billion, up from US$1.23 billion.

Shopify’s net income excluding the impact of equity investments totalled US$344 million for the quarter, up from US$173 million in the same quarter last year.

Daniel Chan, a TD Cowen analyst, said the results show Shopify has a leadership position in the e-commerce world and “a continued ability to gain market share.”

In its outlook for its fourth quarter of 2024, the company said it expects revenue to grow at a mid-to-high-twenties percentage rate on a year-over-year basis.

“Q4 guidance suggests Shopify will finish the year strong, with better-than-expected revenue growth and operating margin,” Chan pointed out in a note to investors.

This report by The Canadian Press was first published Nov. 12, 2024.

Companies in this story: (TSX:SHOP)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

RioCan cuts nearly 10 per cent staff in efficiency push as condo market slows

Published

 on

 

TORONTO – RioCan Real Estate Investment Trust says it has cut almost 10 per cent of its staff as it deals with a slowdown in the condo market and overall pushes for greater efficiency.

The company says the cuts, which amount to around 60 employees based on its last annual filing, will mean about $9 million in restructuring charges and should translate to about $8 million in annualized cash savings.

The job cuts come as RioCan and others scale back condo development plans as the market softens, but chief executive Jonathan Gitlin says the reductions were from a companywide efficiency effort.

RioCan says it doesn’t plan to start any new construction of mixed-use properties this year and well into 2025 as it adjusts to the shifting market demand.

The company reported a net income of $96.9 million in the third quarter, up from a loss of $73.5 million last year, as it saw a $159 million boost from a favourable change in the fair value of investment properties.

RioCan reported what it says is a record-breaking 97.8 per cent occupancy rate in the quarter including retail committed occupancy of 98.6 per cent.

This report by The Canadian Press was first published Nov. 12, 2024.

Companies in this story: (TSX:REI.UN)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version